New combo therapy shows promise for rare blood cancer

NCT ID NCT02717624

Ongoing Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This early-stage trial tests two new drug combinations for people with untreated mantle cell lymphoma, a rare blood cancer. One group gets acalabrutinib plus standard chemo and an antibody; the other gets acalabrutinib plus a targeted pill and the same antibody. The main goal is to check safety and find the best doses. About 72 adults will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acalabrutinib combined with bendamustine and rituximab, or with venetoclax and rituximab
What this could lead to: If successful, this could point toward a more effective first treatment for mantle cell lymphoma, potentially improving how long patients stay in remission.
What could go wrong: This is a very early (Phase 1) trial with only 72 people, so the main goal is safety, not proof of effectiveness. The combination drugs also have known side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL)

Contacts and locations

Locations

Research Site

Louisville, Kentucky, 40207, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Hackensack, New Jersey, 07601, United States
Research Site

Morristown, New Jersey, 07960, United States
Research Site

Lake Success, New York, 11042, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Seattle, Washington, 98122, United States
Research Site

Bologna, 40138, Italy
Research Site

Krakow, 30-510, Poland
Research Site

Lodz, 93-510, Poland
Research Site

Olsztyn, 10-228, Poland
Research Site

Warsaw, 02-106, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.